Why a negative exome result does not rule out a genetic condition: coverage gaps, structural variants, repeats, mosaicism and interpretation limits.
Why does WES miss some changes?
WES is designed to capture most protein-coding exons. However, many regulatory and noncoding regions influence gene function and are not reliably covered by a typical exome assay. A disease-causing change outside the captured regions may therefore go undetected.
The name “whole-exome sequencing” does not guarantee 100% coverage of all exons in every gene. The assay, sample preparation and sequencing quality all matter.
Incomplete coverage and difficult regions
Certain genes are hard to sequence or align because of extreme base composition, highly similar sequences or pseudogenes. Clinically important exons may have insufficient read depth, leaving gaps in a negative report.
If the clinical suspicion points strongly to a particular gene, discuss coverage of its relevant exons and whether another assay can examine any poorly covered regions. Overall average depth alone is not enough.
Structural variants, CNVs and repeat expansions
Large deletions or duplications, balanced translocations, inversions and expanded DNA repeats may require different methods. Some exome-analysis pipelines detect certain copy-number variants (CNVs), but performance and validation vary by laboratory.
Depending on the suspected condition, CMA, karyotyping, WGS or focused repeat-expansion testing may provide additional information. Standard exome protocols often cannot reliably assess repeat-expansion disorders.
Mosaicism and low-frequency variants
In mosaicism, a genetic change is present in only a subset of cells. A variant found at very low frequency in blood, or mainly in another tissue, may not be identified by routine blood-based WES.
Sequencing depth, tissue selection and the analysis pipeline affect mosaic-variant detection. The absence of a variant in blood does not necessarily describe every tissue.
Medical knowledge is also limited
Sometimes the laboratory detects a variant accurately but current evidence does not establish whether it causes disease. Such findings may be classified as variants of uncertain significance (VUS). New research can change how variants are interpreted over time.
A negative finding or a VUS should not, by itself, trigger major treatment changes, cessation of medical follow-up or unplanned testing of relatives.
What comes after a negative result?
Start by reviewing whether the laboratory received detailed symptoms and family history. A clinician can reassess coverage of important genes and consider reanalysis of existing data when appropriate.
Depending on the presentation, next steps could involve CMA, karyotyping, WGS, mitochondrial testing, repeat-expansion assays or tissue-specific investigations. The best test is the one most likely to answer the clinical question—not necessarily the largest one.
Frequently asked questions
Does WES detect every mutation?
No. Some changes are outside the targeted regions, some are technically difficult to call, and not all disease mechanisms are currently understood.
When might reanalysis be useful?
A specialist may consider reanalysis when symptoms evolve, new evidence appears or a meaningful interval has passed since the original interpretation.
Scientific resources for further reading
For case-specific advice and current laboratory requirements, consult our services or genetic counseling team.
